Polyethylene Glycol Antibody (PEG-B-47)

Product Discontinued

Polyethylene Glycol Antibody (PEG-B-47) Summary

• Immunogen: KLH-PEG with terminal methoxy group was used as an immunogen.
• Specificity: KLH-PEG with terminal methoxy group was used as an immunogen. This antibody recognizes the terminal methoxy group of the PEG molecule.
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • ELISA 5-10micrograms/mL
  • Immunohistochemistry 1ug/ml - 5ug/ml
  • Immunohistochemistry-Paraffin 1ug/ml - 5ug/ml
  • Western Blot 200ng/ml - 1ug/ml
• Application Notes: This Product is useful for ELISA 5-10micrograms/mL, Immunohistochemistry-Paraffin, Western BlotThis product is useful for ELISA 5-10micrograms/mL

Reactivity Notes

This antibody recognizes the terminal methoxy group of the PEG molecule. This antibody does not cross react with non-specific targets in blood or serum.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: 0.05% BSA and 50% Glycerol, pH 7.4
• Preservative: 0.01% Sodium Azide
• Purity: Protein A purified

Notes

By detecting the methoxy group of the PEG molecule itself, anti-PEG-47 is useful in measuring the pharmacokinetics of PEG-modified molecules in vivo. Data indicate that anti-PEG-47 detects various length Y-chain PEG molecules as well as single chain PEG molecules with equal affinity (See figure 4). Does not cross react with non-specific targets in blood or serum. Manufactured incorporating RabMab® technology under Epitomics US patents, No 5675,063 and 7,429,487, owned by Abcam.

Alternate Names for Polyethylene Glycol Antibody (PEG-B-47)

• 1,2-Dihydroxyethane
• 1,2-ethanediol
• 107-21-1
• 2-hydroxyethanol
• Ethane-1,2-diol
• Glycol alcohol
• glycol
• monoethylene glycol

Background

Polyethylene glycol(PEG)is a family of long chain polymers attached to a glycerine backbone. It is a nonionic, nontoxic, biocompatible, strongly hydrophilic polymer, which has a large exclusion volume in aqueous solution (1). The covalent attachment of PEG is now commonly used to modify a variety of proteins and drugs (2,3). The modification of a biopharmaceutical with polyethylene glycol (PEG) increases its hydrodynamic radius, reduces immunogenicity and proteolytic cleavage. Other benefits include decelerated renal excretion, improved stability towards proteolysis and increased solubility of the biopharmaceutical in aqueous solutions (4). As examples, PEG-adenosine deaminase (Adagen) is used for the treatment of severe combined immunodeficiency syndrome, PEGasparaginase (Oncaspar) is used for the treatment acute lymphoblastic leukemia, PEGinterferon alpha2a (Pegasys) is used for the treatment Hepatitis C, Branched PEGanti-VEGF aptamer (Pegaptanib, Macugen) is used for the treatment Macular degeneration(age-related) (5). An Anti-PEG antibody can be used to monitor a drugs pharmacokinetics, including distribution, metabolism and excretion. In addition, it can be used for the quality control of pegylated molecules in ELISA, WB and flow cytometery.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.